Planned OABI stock sales by Charles Berkman (NASDAQ: OABI)

Rhea-AI Filing Summary

Orchestra BioMed (OABI) insider Charles S. Berkman has filed a Rule 144 notice for planned stock sales. The filing covers intended sales of 6,891 and 9,541 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70.

The shares to be sold were acquired as restricted stock compensation from the issuer, including 13,542 shares on February 16, 2026 and 18,750 shares on February 18, 2026. The notice also reports a prior sale on December 8, 2025 of 8,044 common shares for gross proceeds of $15,773.84. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company.

Insights

Equity markets analyst

Routine Rule 144 filing for planned OABI insider share sales.

This notice shows Charles S. Berkman intends to sell blocks of Orchestra BioMed common stock under Rule 144, totaling 6,891 and 9,541 shares with specified market values. The shares originate from recent restricted stock compensation awards from the issuer.

A prior sale of 8,044 shares for $15,773.84 over the past three months is also disclosed, which Rule 144 requires to track aggregate volume. Such filings are common for insiders monetizing equity awards and, on their own, do not signal a change in company fundamentals. The representation that the seller knows no undisclosed material adverse information reinforces that this is framed as an ordinary-course liquidity transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES 200 W CIVIC CENTER DR. 4TH FLOOR SANDY UT 84070	6891	11714.70	143955400	02/17/2026	NASDAQ
COMMON	MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES 200 W CIVIC CENTER DR. 4TH FLOOR SANDY CA 84070	9541	16219.70	143955400	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	02/16/2026	RESTRICTED STOCK	ISSUER			13542	02/16/2026	COMPENSATION
COMMON	02/18/2026	RESTRICTED STOCK	ISSUER			18750	02/18/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Charles S Berkman 5980 HORTON STREET SUITE 600 Emeryville CA 94608	COMMON	12/08/2025	8044	15773.84

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the OABI Rule 144 filing by Charles S. Berkman disclose?

The filing discloses planned sales of Orchestra BioMed (OABI) common stock by Charles S. Berkman under Rule 144. It details share amounts, estimated market values, acquisition dates as restricted stock compensation, and a prior sale in December 2025, plus a representation about no undisclosed adverse information.

How many OABI shares does Charles S. Berkman plan to sell under this Rule 144?

The notice covers planned sales of 6,891 and 9,541 Orchestra BioMed common shares. These sales are to be executed through Morgan Stanley Smith Barney LLC on NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70, respectively.

How did Charles S. Berkman acquire the OABI shares he plans to sell?

The shares were acquired as restricted stock compensation from Orchestra BioMed. The filing lists 13,542 common shares received on February 16, 2026 and 18,750 shares on February 18, 2026, both labeled as compensation from the issuer rather than open-market purchases or gifts.

What past OABI stock sales by Charles S. Berkman are reported in the filing?

The document reports a prior sale of 8,044 Orchestra BioMed common shares on December 8, 2025. Gross proceeds from that transaction were $15,773.84, and this disclosure helps ensure Rule 144 volume limits account for all recent sales related to the same seller.

Which broker and exchange are involved in the planned OABI sales?

The planned OABI sales are listed through Morgan Stanley Smith Barney LLC Executive Services as broker. The filing specifies that the common shares are intended to trade on the NASDAQ exchange, with approximate sale dates of February 17 and 18, 2026 for the two share blocks.

Does the OABI Rule 144 filer claim to know any undisclosed negative information?

No. By signing the Rule 144 notice, the person for whose account the securities will be sold represents that they do not know any material adverse information about Orchestra BioMed’s current or prospective operations that has not already been publicly disclosed.